Margaret (Margie) McGlynn is an alumna of the University at Buffalo and a major donor to the Margaret Hempling McGlynn Endowed Chair in Clinical Pharmacy in the UB School of Pharmacy and Pharmaceutical Sciences. She received both her BS in pharmacy and her MBA in marketing from the University at Buffalo. During her career in the private sector, Margie spent 26 years at Merck, where she served in leadership roles in marketing, new product development, and managed care. Her final position at Merck was as President, Global Vaccines and Anti-Infectives. After retiring from Merck, Margie served for 4 years as president and chief executive officer of the International AIDS Vaccine Initiative (IAVI), a product development partnership that helps accelerate HIV vaccine development by bridging government and philanthropic funding with academic and industry vaccine research and development capabilities. Margie also serves on the boards of Vertex Pharmaceuticals, Amicus Therapeutics, Orphan Technologies, and Air Products and Chemicals.
Margie’s patient advocacy is focused on homocystinuria, a metabolic disorder related to the amino acid methionine. Currently, she is the president of the board of HCU Network America, a patient advocacy organization she co-founded to provide support for patients and families affected by homocystinuria. She is also president of the Hempling Foundation for Homocystinuria Research, which she established to support research on new therapies for HCU in honor of her late sisters, Judy and Susie Hempling, who passed away due to homocystinuria in the early 1970s. Margie is committed to finding a cure for homocystinuria so someday no children will suffer as her sisters did. She hopes no families will need to deal with the impact of this devastating illness on their family members or will suffer from the fear of passing the disease along to their children.